| Dokumendiregister | Sotsiaalministeerium |
| Viit | 1.4-2/1699-1 |
| Registreeritud | 04.07.2024 |
| Sünkroonitud | 05.07.2024 |
| Liik | Sissetulev kiri |
| Funktsioon | 1.4 EL otsustusprotsess ja rahvusvaheline koostöö |
| Sari | 1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik) |
| Toimik | 1.4-2/2024 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | World Health Organization |
| Saabumis/saatmisviis | World Health Organization |
| Vastutaja | Triin Uusberg (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond) |
| Originaal | Ava uues aknas |
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
... ENCLS.: (2)
Ref.: C.L.29.2024
...
The World Health Organization (WHO) presents its compliments to Member States and Associate Members and would like to inform that all recommendations made by the 46th WHO Expert Committee on Drug Dependence (ECDD), held in October 2023, were accepted by the 67th UN Commission on Narcotic Drugs.
WHO further has the pleasure of announcing that the 47th Expert Committee on Drug Dependence (ECDD) will meet from 14 to 18 October 2024 in Geneva, Switzerland. Given that WHO Expert Committee meetings are of a closed nature, this circular letter serves to notify Member States of the agenda of the 47th ECDD, which are in the Annex I file, attached for reference.
WHO is mandated by the 1961 and 1971 International Drug Control Conventions to make recommendations to the UN Secretary-General on the need for and level of international control of psychoactive substances. To fulfil this mandate, WHO convenes the ECDD to advise on appropriate international drug control measures in view of a substance’s ability to lead to public health harms as a result of their psychoactive properties, as well as its therapeutic applications.
Although the meetings are of a closed nature, Member States, Associate Members, individuals, and representatives of public and private institutions and civil society who wish to present information to the Expert Committee on issues related to the meeting agenda are invited to attend a virtual information meeting (public consultation) on 14 October 2024. The purpose of the information meeting is to afford the Expert Committee the opportunity to receive presentations and to question representatives of interested parties concerning data that have been provided about substances on the ECDD agenda. Registration information will be made available on the ECDD website in due course: Forty-seventh Expert Committee on Drug Dependence (who.int).
As in the past and in line with the publication “Guidance on the WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6),1 Member States and Associate Members can also contribute to the ECDD review process by providing up to date and accurate information concerning the substances under review in advance of the meeting. For this purpose, and as per previous practice, a questionnaire will be sent to Member States and Associate Members to gather country information on the legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation.
1 http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=90.
Page 2
C.L.29.2024
... Annex II to this Circular Letter contains a list of national focal points officially designated by Member States and Associate Members in previous years who provide country information to the ECDD through the Member State Questionnaire referred to above. If the focal point information requires changes or amendments, Member States and Associate Members are invited to inform the WHO ECDD Secretariat by email to [email protected] by 15 July 2024 with the subject “47ECDD Focal Point: (Country Name)”.
If the individual on the list is still the official focal point for completing the ECDD Member State Questionnaire this year and if no additions or amendments to focal point details are made by 15 July 2024, the focal point from the list will be given further instructions and direct access to online questionnaires by the WHO Secretariat. Results of the questionnaires will be prepared as a report as part of the 47th ECDD substance review process.
In addition to the questionnaire, Member States and Associate Members are also encouraged to provide any additional relevant information (unpublished or published) on the agenda by the 47th ECDD by emailing [email protected] with the subject “Ref: C.L.29.2024”.
Finally, all technical reports and recommendations made by the ECDD are available online through the recently launched ECDD Information Repository (https://ecddrepository.org/en).
The World Health Organization takes this opportunity to renew to Member States and Associate Members the assurance of its highest consideration.
GENEVA, 3 July 2024
47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE
14–18 October 2024
Provisional Agenda
----
Information Session (Public Consultation)
14 October 2024
Virtual
10:00–12:00 CEST
1. Welcome and opening of the meeting
2. Role and Mandate of the WHO Expert Committee on Drug Dependence (ECDD)
3. WHO ECDD review procedure and processes
4. Presentations and statements from participants
47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE
14–18 October 2024
Provisional Agenda
47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE
14–18 October 2024
Closed Session
Geneva, Switzerland
1. Procedural matters and updates
(a) Opening of the meeting and welcoming remarks
(b) Procedural matters
(i) Confidentiality of undertaking
(ii) Declarations of Interest
(iii) Election of Chair, Co-Chair, and Rapporteur
(iv) Adoption of the agenda
2. Updates on priorities from international agencies
(a) Briefings from international agencies on their work on the public health dimension of the world drug problem
(b) Updates on WHO ECDD meetings and recommendations
(i) Recommendations and outcomes of 46th ECDD
(ii) Recommendations from working group on substance surveillance
3. Informal update: ECDD review of coca leaf1
1 There has been a notification from a Party to the 1961 or the 1971 Convention concerning the scheduling of a
substance (Guidance on WHO review of psychoactive substances for international control, para 19(1)). In June 2023, WHO received an official notification from a Member State to conduct a critical review of coca leaf. Accordingly, in accordance with the Guidance on the WHO review of psychoactive substances for international control, a critical review of coca leaf is planned to be conducted in 2025 for the consideration of the Expert Committee on Drug Dependence. An informal update on preparations for such critical review will be presented at this meeting.
47TH WHO EXPERT COMMITTEE ON DRUG DEPENDENCE
14–18 October 2024
4. Critical reviews: Recommendations on the scope of international control2
(a) Synthetic cannabinoids
(i) hexahydrocannabinol (HHC)
(b) Novel synthetic opioids
(i) N-pyrrolidino protonitazene (protonitazepyne)
(ii) N-pyrrolidino metonitazene (metonitazepyne)
(iii) Etonitazepipne (N-Piperidinyl etonitazene)
(iv) N-Desethyl-Isotonitazene
(c) Dissociative-type substance
(i) 3-OH-PCP (3-Hydroxy-phencyclidine)
(d) Cathinone/stimulant
(i) N-ethylheptedrone (Ephylon)
(e) Medicine3
(i) Carisoprodol
5. Finalization of meeting report
= = =
2 Information was brought to WHO’s attention that these substances are clandestinely manufactured, of especially
serious risk to public health and society, and of no recognised therapeutic use by any Party (Guidance on WHO review of psychoactive substances for international control, para 19(4)).
3 The pre-review of a substance has resulted in an Expert Committee recommendation for critical review (Guidance on WHO review of psychoactive substances for international control, para 19(3)).
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Afghanistan
Albania Linda Ternova Specialist
Regulation Sector of Pharmaceutical Market and Medical Devices Ministry of Health and Social Protection, Albania
Algeria Ghrieb Houria Doctor
Narcotics, Psychotropics and Chemical Precursors, General Direction of Pharmacy and Health Equipment, Algerian Health Ministry
Andorra Carla Lobaco Valls Technical Officer Department of Health Resources and Medicines
Andorra Carme Pallarés Papaseit Department of Health Resources and Medicines
Angola
Antigua and Barbuda
Argentina G. Rebaldería Pharmacist
Director of Surveillance of Substances Subject to Special Control Argentinian Ministry of Health
Armenia Hasmik Martirosyan Armenian Ministry of Health [email protected]
Australia
Research and International Policy Section Alcohol & Other Drugs Branch, Population Health Division Australian Government Department of Health and Aged Care
[email protected] 30 April 2024
Australia [email protected]
Austria Raphael Bayer Head of Division
Section VI, Department 6 Federal Ministry of Social Affairs, Health, Care and Consumer Protection
Azerbaijan Telman Suleyman Oglu Mammadhassanov [email protected]
Bahamas
Bahrain Samar Yousef Salem Senior Pharmacist Ministry of Health [email protected]
Bangladesh Habibur Rahman Khan Additional Secretary Health Services Division, Ministry of Health & Family Welfare
Barbados Lindsay Bynoe Assistant Director for Drug Regulation Ministry of Health [email protected]
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Belarus Aleksey Kralko Ministry of Health [email protected]
Belgium Lies Gremeaux Head of Unit illicit Drugs, Reitox National Focal Point
Epidemiology and Public Health, Sciensano, Ministry of Health
Belize
Benin Saturnin Bognon State-certified Pharmacist, Head of Pharmaceutical Establishments Department
Pharmaceutical Establishments Department
Bhutan Dil Kumar Subba Department of Public Health, Ministry of Health
Bolivia (Plurinational State of) Maria Julia Carrasco [email protected]
Bosnia and Herzegovina [email protected]; [email protected]
Bosnia and Herzegovina Sabina Šahman Department for Health, Ministr of the Civill Affairs of Bosnia and Herzegovina
Botswana Vivian Sebako Chief Pharmacist Department of Clinical Services, Ministry of Health and Wellness
Brazil Renata de Morais Souza, Moema Luisa Silva Macedo Manager
Management of Controlled Products GPCON/GGMON/DIMON/ANVISA Controlled Substances Office Brazilian Health Regulatory Agency – ANVISA
Brazil Natalia Jorge e Costa International Affairs Office, Brazilian Health Regulatory Agency - ANVISA, AINTE/ GADIP/ANVISA
Brunei Darussalam Hajah Zanatul ‘Aini Haji Zainin (Ms) Acting Director of Pharmaceutical Services
Department of Pharmaceutical Services, Ministry of Health
Bulgaria Slaveyka Nikolova Chief Expert at the Health Promotion Department Health Promotion and Prophylaxis of the Diseases and Addictions Directorate
Bulgaria Alexander Panayotov Head of the National Focus Center Department
Mental Health and Addiction Prevention Directorate, National Center for Public Health and Analysis
Burkina Faso [email protected]
Burundi Israël Nimubona [email protected]
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Cabo Verde Zania Correia e Silva
Commission for the Coordination of Alcohol and Other Drugs, Ministerio da Saude e da Seguranca Social
Cambodia Chhit Sophal Director Department of Mental and Substance Abuse, Ministry of Health
Cameroon Ketchozo Loko Wilfried [email protected]
Canada
International Relations Unit, Office of Drug Policy and Science, Controlled Substances Directorate, Health Canada, Government of Canada
[email protected] 4/26/2024
Central African Republic
Chad Haoua Haroun Saker Deputy Director of Pharmacy and Medicine
Ministry of Public Health [email protected]
Chile Javiera Erazo Leiva Advisor Department of Mental Health/DIPRECE, Ministry of Health
China Zhendong HUA Deputy Director National Narcotics Laboratory [email protected]
China Yan ZHENG Official Office of National Narcotics Control Commission
China Peng XU Senior Expert National Narcotics Laboratory [email protected]
Colombia Oscar Ricardo Santana
Observatorio de Drogas de Colombia Dirección de Políticas de Drogas y Actividades Relacionadas Ministerio de Justicia y del Derecho
Colombia [email protected]
Colombia A. Peñuela Advisor to the Minister's Office
Coordinator of the Social Coexistence and Citizenship Group of the Directorate of Promotion and Prevention
Comoros
Cook Islands Tereapii Uka Central Policy and Planning Office [email protected]
Costa Rica Marchena Vasquez [email protected]
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Côte d'Ivoire Ernest Zotoua [email protected]
Croatia Romana Katalinić Head of Sector
Administration for Primary Health Care, Health Tourism, Medicines and Medical Products, Public Health and Public Health Protection Ministry of Health
Cuba
Cyprus John Kkolos Pharmacist Pharmaceutical Services, Ministry of Health
Czechia Vlastimil Brandejs Inspectorate Department, Narcotic and Psychotropic Substances Ministry of Health
Democratic People's Republic of Korea
Kim Jong Guk
Democratic Republic of the Congo Ghislaine Mbelu Kanyunya [email protected]
Denmark Kari Gragaasen Chief Consultant Head of Focal Point, Prevention, National Board of Health
Djibouti
Dominica Laura Esprit Chief Medical Office Ministry of Health, Wellness and New Health Investment
Dominica Anna Royer-Edmund Chief Pharmacist Ministry of Health, Wellness and New Health Investment
Dominican Republic [email protected]
Dominican Republic Francisca Dalia Castillo Sanchez Head of the Assistive Technology Department
General Directorate of Medicines, Food and Health Products (DIGEMAPS), Ministry of Public Health
Ecuador María Ignacia Páez Monge
International Drug Commissioner and Head of the Management functions of the Project for the Creation and Implementation of Services of the Community Mental Health Network and State Addiction Recovery Centers
Ecuador Ileana Isabel Espinosa Soto
Project for the Creation and Implementation of Services of the Community Mental Health Network and State Addiction Recovery Centers,
Egypt [email protected]
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
El Salvador José Mauricio Bermúdez Recinos Focal Point of the Ministry of Health of El Salvador
Health Technology Department, Ministry of Health
Equatorial Guinea
Eritrea Michael Girmay Haile [email protected]
Estonia Olga Kamp Specialist in the Inspection Bureau State Agency of Medicines, Ministry of Health
Eswatini
Ethiopia Baharu Zewdie Moya [email protected]
Faroe Islands
Fiji Ilisabeta May Pesamino Chief Pharmacist Pharmaceutical & Biomedical Services/Ministry of Health & Medical Services
Finland Katja Pihlainen Finnish Medicines Agency, Ministry of Health
France Luciano Amato Acting Head of Department
Regulation of narcotics and psychotropic substances, National Agency for the Safety of Medicines and Health Products
Gabon Okouyi Ndakissa Directorate of Medicines and Pharmacy Ministry of Health
Gambia
Georgia Ekaterine Paposhvili Senior Specialist
Division of Legal Circulation of Narcotic Drugs, LEPL State Regulation Agency for Medical Activities Ministry of Labour, Health and Social Affairs of Georgia
Germany Annette Hinze
Division 122 - Narcotics Law, Traffic in Narcotics, International Narcotic Drug Affairs Federal Ministry of Health
Ghana Martha Gyansa-Lutterodt Director Pharmaceutical Services, Ministry of Health
Greece Ioanna Siamou Responsible for the Early Warning System University Mental Health Research Institute
Greece Maria Kouloumpi Head of the Directorate of Dependencies Hellenic Ministry of Health [email protected];[email protected]
Grenada
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Guatemala Karem Ermely Sagastume Aguirre [email protected]
Guatemala Shuandy Alejandra Milian Recinos [email protected]
Guatemala Beatriz Eugenia Batres Rivera [email protected]
Guinea
Guinea-Bissau
Guyana
Haiti Marie Judith Robuste Roche Ministry of Health [email protected]
Honduras Alex Virgilio Santos Moreno General Director of the Honduran Institute for the Prevention of Alcoholism
Honduran Institute for the Prevention of Alcoholism, Drug Addiction and Drug Dependence (IHADFA)
Hungary Tímea Kahlesz Deputy Head of Department EMMI Pharmaceutical and Medical Technology Department
Iceland Bjarni Sigurðsson Ministry of Health [email protected]
India Rakesh Chadda Professor and Head
Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences
Indonesia Agusdini Banun Saptaningsih Director of Pharmaceutical Production and Distribution
Directorate General of Pharmaceutical Care and Medical Devices,
Iran (Islamic Republic of) Mina Azhoogh [email protected]
Iraq Emad Abdulrazzaq Abdulghani Ministry of Health [email protected]
Ireland Conor Brennan Department of Health [email protected]
Ireland Alan Bell Department of Health [email protected]
Israel Paola Rosca Head of the Addiction Treatment Departm Ministry of Health [email protected]
Israel Tal Lavy
The Competent Authority for Narcotics, Psychotropics and Precursors Pharmaceutical Administration
Italy Pietro Canuzzi Medical Doctor Ministry of Health - Directorate general of Health Prevention
Itay Rocco Signorile Central Narcotics Office, Ministry of Health
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Jamaica Dr Jacquiline Bisasor McKenzie Chief Medical Officer Ministry of Health & Wellness [email protected]
Jamaica Michael Tucker Executive Director National Council on Drug Abuse (NCDA)
Jamaica Uki Atkinson Research Analyst National Council on Drug Abuse (NCDA)
Japan
Compliance and Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau
Jordan Malak AlMahirah
Head of Narcotics, Psychotropic Substances and Chemical Precursors Department, Jordan Food and Drug Administration
Kazakhstan Prilutskaya Marina Republican Scientific and Practical Center of Mental Health
Kenya Anthony Toroitich [email protected]
Kenya Simon Njuguna [email protected]
Kiribati Biribo Kararaiti Chief Pharmacist Ministry of Health and Medical Services
Kuwait Ali Abdulmohsen Jaragh Pharmacist Control of Licenses for Narcotic Drugs and Psychotropic Substances Department
Kyrgyzstan Kanyshai Damirbek Drug Trafficking Control Department, Ministry of Foreign Affairs
Lao People's Democratic Republic Khatthanaphone Phandoangsy Head of Health Promotion and Nutrition Unit
Department of Hygiene and Health Promotion, Ministry of Health
Latvia Linda Veisberga Ministry of Health [email protected]
Lebanon Marie-Therese Matar Head of Narcotics Department Ministry of Public Health [email protected]
Lesotho Masello Sello [email protected]
Liberia Dr David Zubah Sakui National Controlled Substance Coordinator
Division of Pharmaceutical Sciences (DPS)
Libya
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Lithuania Rima Mačiūnienė Head of Drug Precursors Control and Risk Assessment Division
Drug Precursors Control and Risk Assessment Division, Drug, Tobacco and Alcohol Control Department
Luxembourg Alain Origer National Drug Coordinator Ministry of Health [email protected]
Madagascar Maximine Ravaoarimanana Director of Pharmacy Laboratories and Traditional Medicine
Malawi Michael Udedi Assistant Director of Clinical Services (Mental Health and Substance Abuse)
Malaysia Rohaida Binti Zakaria Senior Principal Assistant Director Pharmaceutical Services Division, Ministry of Health
Maldives Aishath Mohamed Deputy Director General, Pharmaceuticals
Medicine and Therapeutic Goods Division, Maldives Food and Drug Authority
Mali Mahamadou Ousmane Maiga [email protected]
Malta Victor P. Pace Office of the Superintendence of Public Health, Department for Health Regulation
Marshall Islands Julia Alfred Ministry of Health [email protected]
Mauritania Hamoud Fadel Yamohomed Director of Pharmacy and Laboratories Ministry of Health [email protected]
Mauritius Nitish Raj Sokool Officer-in-Charge Harm Reduction Unit, Ministry of Health and Wellness
Mauritius Anil Jhugroo Advisor on Substance Abuse Ministry of Health and Wellness [email protected]
Mexico Angélica Juárez Ramírez Specialized Reviewer COFEPRIS representative, Federal Committee for Protection from Sanitary Risks
Micronesia (Federated States of) Benido Victor [email protected]
Monaco Isabelle Kessedjian Head of Division Pharmacy Inspector, Health Products Division
Mongolia Luvsandagva Purevdorj [email protected]
Montenegro Jasna Sekulic Ministry of Health [email protected]
Morocco Hassan Elkarimi [email protected]
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Morocco Jallal Toufiq
Professor of Psychiatry, Rabat Faculty of Medicine, Director of the National Centre on Drug Abuse Prevention, Treatment and Research, Director of the Moroccan Observatory on Drugs and Drugs Addictions
Mozambique Flavio Mandlate [email protected]
Myanmar Nanda Myo Aung Wan Program Manager/ Consultant Psychiatrist
Drug Dependency Treatment and Research Unit, Ministry of Health and Sport
Namibia Ester Mvula Senior Pharmacist Ministry of Health & Social Services [email protected]
Nauru Richard Leona Chief Surgeon Ministry of Health [email protected]
Nepal
Netherlands (Kingdom of the) Matthijs Geilenkirchen
Nutrition, Health Protection and Prevention Department, Ministry of Health, Welfare and Sport
[email protected] 29 April 2024
New Zealand Tania Jones Regulatory Practice and Analysis, Medsafe
Nicaragua Karla Vanessa Delgado Martinez Director of Pharmacy Ministry of Health [email protected]
Niger Haoua Na Allah Alou [email protected]
Nigeria Rafiu Akanbi Folarin Head Narcotics and Drug Abuse Programme
Narcotics and Drug Abuse Programme, Pharmaceutical Services Division, Department of Food and Drug Services, Federal Ministry of Health
Niue
North Macedonia
Norway Anne S. Onsgård Sagabråten Narcotic Drugs Control, Norwegian Medicines Agency
Oman Mahmood Al Abri [email protected]
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Oman
Directorate General of Pharmaceutical Affairs and Drug control, Ministry of Health
Pakistan Rizwan Taj Professor Ministry of Health [email protected]
Palau Clarette Matlab Chief Pharmacist
Division of Ancillary Services, Bureau of Hospital and Clinical Services, Ministry of Health
Palau [email protected]
Palau Marla Ito [email protected]
Panama Delia De Ycaza Head of the Mental Health Section of the General Directorate of Public Health
General Directorate of Health of the Ministry of Health
Papua New Guinea Vicky Wari Program Manager-Non Communicable Diseases
Public Health Division, National Department of Health
Paraguay Laura Patricia Perez Villaverde [email protected]
Paraguay Zaira Francesca Stumpfs Bigarella [email protected]
Peru Judith Castañeda Alcántara Head of Functional Unit of Controlled Products
DIGEMID – General Directorate of Medicines, Supplies and Drugs
Philippines
Poland Michał Kidawa Polish Reitox Focal Point
Information Centre for Drugs and Drug Addiction (CINN) National Bureau for Drug Prevention
Portugal Graça Vilar Director of Planning and Intervention Services Directorate
Intervention Service for Addictive Behaviours and Addictions General Directorate for Intervention on Addictive Behaviours and Dependencies SICAD
Puerto Rico
Qatar Majid Ali Al Abdulla Senior Consultant Psychiatrist
Director of addiction and CL at Hamad Medical Corporation Deputy Chairman of Mental Health Services, Hamad Medical Corporation
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Republic of Korea Hyun Jun Kim Narcotics Policy Division of Ministry of Food and Drug Safety
Republic of Moldova Oleg Costachi
Standing Committee on Drugs Control, Agency for Medicines and Medical Devices
Romania Camelia Bunaciu Senior Advisor Ministry of Health [email protected]
Russian Federation Alyona Ryzova Deputy Head of the Unit for regulatory and Department for regulation of medicines and medical devices, Ministry of Health
Rwanda
Saint Kitts and Nevis puerto rico
Saint Lucia Charlotte Emmanuel Coordinator of the Substance Abuse Advisory Council Secretariat
Substance Abuse Advisory Council Secretariat, Ministry of Health and Wellness
Saint Lucia Paul Caleb Programme Officer Substance Abuse Advisory Council Secretariat, Ministry of Health and Wellness
Saint Vincent and the Grenadines
Samoa Robert Thomsen Assistant Chief Executive Officer HSPQA, Medical and Allied Division [email protected]
San Marino Claudio Muccioli Health Authority Director Health Authority [email protected]
Sao Tome and Principe
Saudi Arabia Adnan Alshammary
Administration of controlled preparations, Executive Management for Regulatory Affairs, Controlled Products Department, Regulatory Affairs Directorate, Drug Sector
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Senegal Moussa DIALLO Pharmacist Inspector Pharmaceutical Regulatory Agency, Ministry of Health and Social Action
Serbia Nataša Savić
Monitoring Centre for Drugs and Drug Addiction, Sector for Medicines and Medical Devices, Psychoactive Controlled Substances and Precursors, Ministry of Health
Seychelles
Sierra Leone
Singapore Ong Lay Tin Personal Assistant to Director (International Cooperation)
Senior Executive (International Cooperation) Public Health Group, Ministry of Health
Slovakia Peter Koreň Reitox National Focal Point
National Monitoring Centre for Drugs, Department of Anti-Drug Strategy Coordination and Drug Monitoring, Ministry of Health of the Slovak Republic
[email protected] 4/8/2024
Slovenia Joze Hren Secretary Directorate of Public Health, Ministry of Health
Solomon Islands Paul Orotaloa Head of Mental Health Services National Mental Health Service, Ministry of Health and Medical Services
Solomon Islands Stephen Araitewa Director Mental Health National Mental Health Service, Ministry of Health and Medical Services
Somalia
South Africa MG Molewa Ministry of Health [email protected]
South Sudan Moses Malual Deng Director General of Pharmaceuticals and Medical Supplies
Ministry of Health [email protected]
Spain Manuel Ibarra Head of Department Inspection & Enforcement
Spanish Agency of Medicines and Medical Products (AEMPS)
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Spain Lidia Fernandez Matellano
Narcotics and Psychotropic Substances Area, Pharmaceutical Inspection and Enforcement Department, Spanish Agency of Medicines and Medical Products (AEMPS)
Sri Lanka S.C. Wickramasinghe Deputy Director General (NCD) Ministry of Health [email protected]
Sudan
Suriname
Sweden Ms Kajsa Mickelsson
Ministry of Health and Social Affairs, Division for Public Health and Health Care
[email protected] 4/8/2024
Switzerland Lucien Colliander
Federal Department of Home Affairs, Federal Office of Public Health, Division of International Affairs, Global Health Section
Switzerland Monika Joos Head of Division Narcotics Swissmedic, Swiss Agency for Therapeutic Products
Syrian Arab Republic Ahmed Al-Salama Mental Health Directorate, Ministry of Health
Tajikistan Salim Abdulazizov [email protected]
Thailand Sujinart Chantharakul Pharmacist
Narcotics Control Division (Standards and Regulations Sub- Division), Food and Drug Administration, Ministry of Public Health
Thailand Saranya Chavanich Pharmacist
Narcotics Control Division (Standards and Regulations Sub- Division), Food and Drug Administration, Ministry of Public Health
Thailand Korapin Na Ranong Expert on Narcotics Epidemiology Narcotics Control Division Food and Drug Administration, Ministry of Public Health
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
Thailand Raththar Benchapalanont Pharmacist Narcotics Control Division Food and Drug Administration, Ministry of Public Health
Timor-Leste Soares Henriques Regulatory Affairs Pharmacist
Pharmacovigilance and Medicine Control Department, National Directorate for Pharmaceutical and Medicines, Ministry of Health
Togo Mouhoudine Yerima Centre National de Pharmacovig [email protected];[email protected]
Tokelau
Tonga Melenaite Mahe Principal Pharmacist Central Pharmacy and Medical Store, Old Vaiola, Ministry of Health
Trinidad and Tobago Anesa Doodnath-Siboo Principal Pharmacist Ministry of Health [email protected]
Tunisia
Türkiye Demet Aydınkarahaliloğlu Head Turkish Medicines and Medical Devices Agency
Pharmacovigilance and Medicine Control Department, National Directorate for Pharmaceutical and Medicines, Ministry of Health
Turkmenistan
Tuvalu
Uganda Hafsa Lukwata Head of Mental Health and Control of Substance Abuse
Mental Health and Control of Substance Abuse Division, Ministry of Health
Ukraine Deputy Director Institute of Psychiatry, Forensic Psychiatric Examination and Drug Monitoring,
Ukraine Irina Pinchuk Director
Institute of Psychiatry of Taras Shevchenko National University of Kyiv, International Technology Transfer Center - Ukraine Head of ISSUP Ukraine National Chapter
Ukraine Yulia YACHNYK Clinical Psychologist Institute of Psychiatry, Taras Shevchenko National University of Kyiv
Annex II: List of focal points designated by Member States in previous years
Country Name Focal Point Job title Institution Email Last update
United Arab Emirates Alia Bin Hussain Head of Regulating Controlled substances Product & Precursor Chemicals Drug Department, Ministry of Health and Prevention
United Kingdom of Great Britain and Northern Ireland
Alberto Oteo Project Manager Drugs Research and Surveillance
Addiction and Inclusion Directorate, Office for Health Improvement & Disparities, Department of Health and Social Care
United Republic of Tanzania Suma Jairo Pharmacist Pharmaceutical Service Unit, Ministry of Health
United States of America Edward Hawkins Senior Pharmacologist and International Drug Control Liaison
Center for Drug Evaluation and research, U.S. Food and Drug Administration
Uruguay Horacio Porciuncula Mental Health Program Area, Ministry of Public Health
Uzbekistan
Vanuatu Jerry Iaruel Tafea Provincial Health Administrator Lenakel Health Office, Ministry of Health
Venezuela (Bolivarian Republic of)
Viet Nam Mhin Tam Nguyen Regulatory Affair Consultant Ministry of Health [email protected]
Yemen
Zambia Nita Besa Head Clinical Care Chainama Hospital [email protected]
Zimbabwe Eneti Siyame Mental Health Manager Ministry of Health and Child Care [email protected]